TriangleNCT04582539 · OUTCOME
Change From Baseline in Hemoglobin at the End of Treatment
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- grams per liter
- Interval / dispersion
- Standard Deviation
- Time frame
- up to 950 days
What was measured
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Analysis population: Full Analysis Set-MDS. Only participants with available data were analyzed.
Groups in this outcome
Zilurgisertib 50 mg QD
Participants with myelodysplastic syndromes (MDS) or multiple myeloma (MM) who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 50 milligrams (mg) once daily (QD) administered as a monotherapy for up to 6 months.
Zilurgisertib 100 mg QD
Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 100 mg QD administered as a monotherapy for up to 6 months.
Zilurgisertib 200 mg QD
Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 200 mg QD administered as a monotherapy for up to 6 months.
Zilurgisertib 400 mg QD
Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 400 mg QD administered as a monotherapy for up to 6 months.
Zilurgisertib 600 mg QD
Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 600 mg QD administered as a monotherapy for up to 6 months.
| Group | Source count |
|---|---|
| Zilurgisertib 50 mg QD | 4 |
| Zilurgisertib 100 mg QD | 5 |
| Zilurgisertib 200 mg QD | 4 |
| Zilurgisertib 400 mg QD | 5 |
| Zilurgisertib 600 mg QD | 3 |
Reported measurements
Baseline
| Group | Source count |
|---|---|
| Zilurgisertib 50 mg QD | 4 |
| Zilurgisertib 100 mg QD | 5 |
| Zilurgisertib 200 mg QD | 4 |
| Zilurgisertib 400 mg QD | 5 |
| Zilurgisertib 600 mg QD | 3 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Zilurgisertib 50 mg QD | 77.7750 | 5.83688 | Not reported | Not reported | Not reported |
| Zilurgisertib 100 mg QD | 75.7200 | 4.00899 | Not reported | Not reported | Not reported |
| Zilurgisertib 200 mg QD | 74.9354 | 5.98330 | Not reported | Not reported | Not reported |
| Zilurgisertib 400 mg QD | 74.6767 | 7.94708 | Not reported | Not reported | Not reported |
| Zilurgisertib 600 mg QD | 79.4139 | 4.14997 | Not reported | Not reported | Not reported |
Change from Baseline at end of treatment
| Group | Source count |
|---|---|
| Zilurgisertib 50 mg QD | 2 |
| Zilurgisertib 100 mg QD | 3 |
| Zilurgisertib 200 mg QD | 2 |
| Zilurgisertib 400 mg QD | 3 |
| Zilurgisertib 600 mg QD | 3 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Zilurgisertib 50 mg QD | -1.7500 | 4.59619 | Not reported | Not reported | Not reported |
| Zilurgisertib 100 mg QD | 10.1333 | 12.87685 | Not reported | Not reported | Not reported |
| Zilurgisertib 200 mg QD | 4.0182 | 7.61104 | Not reported | Not reported | Not reported |
| Zilurgisertib 400 mg QD | 16.9556 | 12.34055 | Not reported | Not reported | Not reported |
| Zilurgisertib 600 mg QD | 69.6667 | 10.40833 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 5.83688
- value
- 77.7750
- group Id
- OG001
- spread
- 4.00899
- value
- 75.7200
- group Id
- OG002
- spread
- 5.98330
- value
- 74.9354
- group Id
- OG003
- spread
- 7.94708
- value
- 74.6767
- group Id
- OG004
- spread
- 4.14997
- value
- 79.4139
- denoms
- counts
- group Id
- OG000
- value
- 4
- group Id
- OG001
- value
- 5
- group Id
- OG002
- value
- 4
- group Id
- OG003
- value
- 5
- group Id
- OG004
- value
- 3
- units
- Participants
- title
- Baseline
- categories
- measurements
- group Id
- OG000
- spread
- 4.59619
- value
- -1.7500
- group Id
- OG001
- spread
- 12.87685
- value
- 10.1333
- group Id
- OG002
- spread
- 7.61104
- value
- 4.0182
- group Id
- OG003
- spread
- 12.34055
- value
- 16.9556
- group Id
- OG004
- spread
- 10.40833
- value
- 69.6667
- denoms
- counts
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 2
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 3
- units
- Participants
- title
- Change from Baseline at end of treatment
- denoms
- counts
- group Id
- OG000
- value
- 4
- group Id
- OG001
- value
- 5
- group Id
- OG002
- value
- 4
- group Id
- OG003
- value
- 5
- group Id
- OG004
- value
- 3
- units
- Participants
- description
- Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
- dispersion Type
- Standard Deviation
- groups
- description
- Participants with myelodysplastic syndromes (MDS) or multiple myeloma (MM) who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 50 milligrams (mg) once daily (QD) administered as a monotherapy for up to 6 months.
- id
- OG000
- title
- Zilurgisertib 50 mg QD
- description
- Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 100 mg QD administered as a monotherapy for up to 6 months.
- id
- OG001
- title
- Zilurgisertib 100 mg QD
- description
- Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 200 mg QD administered as a monotherapy for up to 6 months.
- id
- OG002
- title
- Zilurgisertib 200 mg QD
- description
- Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 400 mg QD administered as a monotherapy for up to 6 months.
- id
- OG003
- title
- Zilurgisertib 400 mg QD
- description
- Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 600 mg QD administered as a monotherapy for up to 6 months.
- id
- OG004
- title
- Zilurgisertib 600 mg QD
- param Type
- MEAN
- population Description
- Full Analysis Set-MDS. Only participants with available data were analyzed.
- reporting Status
- POSTED
- time Frame
- up to 950 days
- title
- Change From Baseline in Hemoglobin at the End of Treatment
- type
- SECONDARY
- unit Of Measure
- grams per liter
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice